Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12485740 | 0.90 | MPO (0.81) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL12487210 | 0.88 | MPO (0.78) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL15347348 | 0.88 | MPO (1.00) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL12486824 | 0.85 | THRB (0.74) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL12487305 | 0.85 | MPO (0.77) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL18826591 | 0.85 | MAPT (0.80) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL14966490 | 0.84 | MPO (0.72) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL14970811 | 0.84 | LMNA (0.69) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL23261486 | 0.84 | CCNK (0.77) | MPOMAPTALDH1A1POLBPKM | |
| SCHEMBL12487273 | 0.84 | MAPT (0.77) | MPOMAPTALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066454-A1 | Antibiotic Tolerance Inhibitors | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-03-06 | — | — | US | claimed |
| EP-2678319-A2 | ANTIBIOTIC TOLERANCE INHIBITORS | The General Hospital Corporation (US) | 2014-01-01 | — | — | EP | claimed |
| WO-2012116010-A2 | ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-30 | — | — | WO | claimed |
| US-20150266827-A1 | Antibiotic Tolerance Inhibitors | THE GENERAL HOSPITAL CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-8877940-B2 | Antibiotic tolerance inhibitors | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-11-04 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140066454-A1 | Antibiotic Tolerance Inhibitors | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-03-06 | — | — | US | disclosed |
| EP-2678319-A2 | ANTIBIOTIC TOLERANCE INHIBITORS | The General Hospital Corporation (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012116010-A2 | ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266827-A1 | Antibiotic Tolerance Inhibitors | CLPP, CFTR, AADAC | MPO 1891/4885MAPT 3775/4885ALDH1A1 1458/4885 |
| US-20140066454-A1 | Antibiotic Tolerance Inhibitors | CLPP, CFTR, AADAC | MPO 1891/4885MAPT 3775/4885ALDH1A1 1458/4885 |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | MPO 2916/4885MAPT 4829/4885ALDH1A1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.